TRUS Biopsy: Does it Still Have a Role?

Michael S. Leapman, MD, is an Associate Professor of Urology, an Associate Professor of Chronic Disease Epidemiology, and Vice Chair of Research in the Department of Urology at Yale University in New Haven, Connecticut. Dr. Leapman also serves as the Clinical Lead for the Prostate and Urologic Cancer Program at the Yale Smilow Cancer Center, where he directs multidisciplinary efforts to improve the care of patients with prostate and other genitourinary cancers. His clinical practice is devoted to the management of prostate and other urologic malignancies, with a particular expertise in robotic and minimally invasive approaches to radical prostatectomy. 

Dr. Leapman earned his medical degree from the University of Maryland in Baltimore. He completed an internship in General Surgery and a residency in Urology at Mount Sinai Hospital in New York, New York. Dr. Leapman then completed a fellowship in Urologic Oncology at the University of California, San Francisco. He earned his Master’s in Health Science from Yale University.

Dr. Leapman’s research focuses on questions related to how advanced imaging, biomarkers, and large-scale data analysis can be applied to improve detection, risk stratification, and management of prostate cancer, and ultimately to improve clinical outcomes. He has authored and co-authored more than 270 articles and book chapters in his field. He has been recognized for his contributions, including the John N. Forrest Jr. Prize for Mentorship in Student Research, Merit Award: Conquer Cancer Foundation of the American Society of Clinical Oncology, Best Poster: European School of Oncology Conference on Active Surveillance, and the First Place Essay, History Section: American Urological Association Western Section.